Menu
← Oncology Approval Tracker
FDA DECISION ·
Inluriyo
imlunestrant · Eli Lilly and Company
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
For adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer after progression on at least one endocrine therapy line.
LAMPGEN ANALYSIS
Why it matters
An oral estrogen receptor antagonist gives a biomarker-directed option after endocrine therapy in ESR1-mutated disease.
What research teams should watch
Arrange validated ESR1 testing at progression and verify prior endocrine exposure before changing treatment.
Related study operations checklist
See the staffing responsibilities, timing, and handoff questions for this study setting.
ESR1-selected advanced or metastatic diseasePRIMARY RECORDS